Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1981 Dec;20(6):747–759. doi: 10.1128/aac.20.6.747

Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria

Peter C Fuchs 1, Ronald N Jones 2, Clyde Thornsberry 3, Arthur L Barry 4, E Hugh Gerlach 5, Herbert M Sommers 6
PMCID: PMC181794  PMID: 6275784

Abstract

The in vitro activity of cefmenoxime (SCE-1365) was evaluated in a multiphased collaborative investigation. Over 7,500 consecutive clinical isolates were tested in five laboratories, and greater than 90% of the following organisms were inhibited by cefmenoxime at the following concentrations: Enterobacteriaceae and non-enterococcal streptococci, ≤0.125 μg/ml; Staphylococcus aureus, ≤2.0 μg/ml; and nonfermenting gram-negative bacilli and Bacteroides fragilis group, ≤32 μg/ml. Both beta-lactamase-producing and -nonproducing Haemophilus influenzae and Neisseria gonorrhoeae were inhibited by cefmenoxime at ≤0.03 μg/ml. The spectrum of cefmenoxime was similar to that of other, newer cephalosporins, particularly cefotaxime. A pronounced inoculum effect was found with some species upon increasing inocula from 105 to 107 colony-forming units per ml, resulting in an approximate eightfold increase in minimum inhibitory concentrations. Cefmenoxime was bactericidal when tested with inocula of 105 colonyforming units per ml, and mean differences between the minimum inhibitory concentration and the minimum lethal concentration were less than one log2 dilution. No significant hydrolysis of cefmenoxime by five different beta-lactamases was detectable, and cefmenoxime exhibited marked inhibition of type I beta-lactamases. Regression and error rate-bounded analyses of results of disk diffusion and reference broth microdilution susceptibility tests were performed on 421 bacterial isolates, and the following tentative zone size breakpoints are proposed: ≥22 mm, susceptible; ≤14 mm, resistant; and 15 to 21 mm, moderately susceptible (indeterminate). These data and cross-resistance studies with other newer cephalosporins indicate marked similarity of in vitro activity within this group of drugs, particularly between cefmenoxime, moxalactam, and cefotaxime. Any one of these could serve as the representative for the disk diffusion testing of this group of drugs if comparable minimum inhibitory concentration breakpoints were used for each drug.

Full text

PDF
747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker C. N., Thornsberry C., Jones R. N. In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains. Antimicrob Agents Chemother. 1980 Apr;17(4):757–761. doi: 10.1128/aac.17.4.757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Thornsberry C., Jones R. N., Fuchs P. C., Gavan T. L., Gerlach E. H. Cefuroxime, an in vitro Comparison with Six Other Cephalosporins. Proc R Soc Med. 1977;70(Suppl 9):63–71. doi: 10.1177/00359157770700S912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry A. L., Thornsberry C., Jones R. N., Gerlach E. H. Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935). Antimicrob Agents Chemother. 1980 Nov;18(5):716–721. doi: 10.1128/aac.18.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fu K. P., Neu H. C. The comparative beta-lactamase resistance and inhibitory activity of 1-oxa cephalosporin, cefoxitin and cefotaxime. J Antibiot (Tokyo) 1979 Sep;32(9):909–914. doi: 10.7164/antibiotics.32.909. [DOI] [PubMed] [Google Scholar]
  5. Fu K. P., Neu H. C. beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. Antimicrob Agents Chemother. 1978 Sep;14(3):322–326. doi: 10.1128/aac.14.3.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Barry A. L., Thornsberry C., Jones R. N., Gavan T. L., Gerlach E. H., Sommers H. M. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing. Antimicrob Agents Chemother. 1980 Jul;18(1):88–93. doi: 10.1128/aac.18.1.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamilton-Miller J. M., Brumfitt W., Reynolds A. V. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. J Antimicrob Chemother. 1978 Sep;4(5):437–444. doi: 10.1093/jac/4.5.437. [DOI] [PubMed] [Google Scholar]
  8. Jones R. N., Fuchs P. C., Gavan T. L., Gerlach E. H., Barry A. L., Thornsberry C. Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother. 1977 Jul;12(1):47–50. doi: 10.1128/aac.12.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones R. N., Fuchs P. C., Sommers H. M., Gavan T. L., Barry A. L., Gerlach E. H. Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin. Antimicrob Agents Chemother. 1980 Apr;17(4):750–756. doi: 10.1128/aac.17.4.750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  11. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sykes R. B., Matthew M. The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics. J Antimicrob Chemother. 1976 Jun;2(2):115–157. doi: 10.1093/jac/2.2.115. [DOI] [PubMed] [Google Scholar]
  13. Thornsberry C., Baker C. N., Jones R. N. In vitro antimicrobial activity of piperacillin and seven other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase producing strains. J Antimicrob Chemother. 1979 Mar;5(2):137–142. doi: 10.1093/jac/5.2.137. [DOI] [PubMed] [Google Scholar]
  14. Tsuchiya K., Kita Y., Yamazaki I., Kondo M., Noji Y., Fugono T. Absorption, distribution and excretion of cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin, in mice, rats, rabbits and dogs. J Antibiot (Tokyo) 1980 Dec;33(12):1532–1544. doi: 10.7164/antibiotics.33.1532. [DOI] [PubMed] [Google Scholar]
  15. Tsuchiya K., Kondo M., Kida M., Nakao M., Iwahi T., Nishi T., Noji Y., Takeuchi M., Nozaki Y. Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1981 Jan;19(1):56–65. doi: 10.1128/aac.19.1.56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Van Landuyt H. W., Pyckavet M. In vitro of cefotaxime against cephalothin-resistant clinical isolates. Antimicrob Agents Chemother. 1979 Jul;16(1):109–111. doi: 10.1128/aac.16.1.109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. WHITE L. A., KELLOGG D. S., Jr NEISSERIA GONORRHOEAE IDENTIFICATION IN DIRECT SMEARS BY A FLUORESCENT ANTIBODY-COUNTERSTAIN METHOD. Appl Microbiol. 1965 Mar;13:171–174. doi: 10.1128/am.13.2.171-174.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Watanakunakorn C., Glotzbecker C. Comparative in vitro activity of LY 127935 (6059-S), seven cephalosporins, three aminoglycosides, carbenicillin, and ticarcillin. J Antibiot (Tokyo) 1979 Oct;32(10):1019–1024. doi: 10.7164/antibiotics.32.1019. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES